Bilosomes as Nanocarriers for the Drug and Vaccine Delivery against Gastrointestinal Infections: Opportunities and Challenges
Source abstract
Abstract
The gastrointestinal tract (GIT) environment has an intricate and complex nature, limiting drugs’ stability, oral bioavailability, and adsorption. Additionally, due to the drugs’ toxicity and side effects, renders are continuously seeking novel delivery systems. Lipid-based drug delivery vesicles have shown various loading capacities and high stability levels within the GIT. Indeed, most vesicular platforms fail to efficiently deliver drugs toward this route. Notably, the stability of vesicular constructs is different based on the different ingredients added. A low GIT stability of liposomes and niosomes and a low loading capacity of exosomes in drug delivery have been described in the literature. Bilosomes are nonionic, amphiphilic, flexible surfactant vehicles that contain bile salts for the improvement of drug and vaccine delivery. The bilosomes’ stability and plasticity in the GIT facilitate the efficient carriage of drugs (such as antimicrobial, antiparasitic, and antifungal drugs), vaccines, and bioactive compounds to treat infectious agents. Considering the intricate and harsh nature of the GIT, bilosomal formulations of oral substances have a remarkably enhanced delivery efficiency, overcoming these conditions. This review aimed to evaluate the potential of bilosomes as drug delivery platforms for antimicrobial, antiviral, antifungal, and antiparasitic GIT-associated drugs and vaccines.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Inhalation and Respiratory Drug Delivery · Advancements in Transdermal Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa P.O. Box 7461686688, Iran
Department of Medical Microbiology, Medical College, Al Muthanna University, Al Muthanna P.O. Box 07835544777, Iraq
College of Applied Science, University of Fallujah, Fallujah, Anbar 31002, Iraq
Department of Pharmacology, Faculty of Medicine, Fasa University of Medical Sciences, Fasa P.O. Box 7461686688, Iran
Department of Movement and Sports Sciences, Ghent University, 9000 Ghent, Belgium
References (86)
Show source-provided references
1. Microbial contamination of drinking water and disease outcomes in developing regions10.1016/j.tox.2004.01.030 ↗
2. Enteric infections10.1007/978-3-319-04220-6_8 ↗
3. Imam, S.S., Alshehri, S., Altamimi, M.A., Almalki, R.K.H., Hussain, A., Bukhari, S.I., Mahdi, W.A., and Qamar, W. (2022). Formulation of Chitosan-Coated Apigenin Bilosomes: In Vitro Characterization, Antimicrobial and Cytotoxicity Assessment. Polymers, 14.10.3390/polym14050921 ↗
4. Bile acid-based advanced drug delivery systems, bilosomes and micelles as novel carriers for therapeutics10.1002/cbf.3732 ↗
5. Nanovesicles-Mediated Drug Delivery for Oral Bioavailability Enhancement10.2147/IJN.S382192 ↗
6. Insight on nano drug delivery systems with targeted therapy in treatment of oral cancer10.1016/j.nano.2023.102662 ↗
7. Mancuso, G., Midiri, A., Gerace, E., and Biondo, C. (2021). Bacterial antibiotic resistance: The most critical pathogens. Pathogens, 10.10.3390/pathogens10101310 ↗
8. Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects10.1016/j.jiph.2021.10.020 ↗
9. Vesicular Nanocarriers: A potential platform for dermal and transdermal drug delivery
10. Stabilization of lipid vesicles: Upcoming strategic insights for product development10.1016/j.molliq.2021.118430 ↗
11. Bilosomes as a promising nanoplatform for oral delivery of an alkaloid nutraceutical: Improved pharmacokinetic profile and snowballed hypoglycemic effect in diabetic rats10.1080/10717544.2022.2110997 ↗
12. Bilosomes: A controlled delivery system for the sustained release of torularhodin during digestion in the small intestine both in vitro and in vivo10.1016/j.colsurfa.2022.130055 ↗
13. Gupta, D.K., Ahad, A., Waheed, A., Aqil, M., Al-Jenoobi, F.I., and Al-Mohizea, A.M. (2022). Bilosomes: A Novel Platform for Drug Delivery, in Systems of Nanovesicular Drug Delivery, Elsevier.10.1016/B978-0-323-91864-0.00004-8 ↗
14. The Influence of Nanoparticle on Vaccine Responses against Bacterial Infection
15. Bilosomes in the context of oral immunization: Development, challenges and opportunities10.1016/j.drudis.2016.03.013 ↗
16. Nanocarriers for transmucosal vaccine delivery10.2174/157341311794653541 ↗
17. Bilosomes: Superior Vesicular Carriers10.2174/1574885514666190917145510 ↗
18. Bilosomes as promising nanovesicular carriers for improved transdermal delivery: Construction, in vitro optimization, ex vivo permeation and in vivo evaluation10.2147/IJN.S278688 ↗
19. Alsaidan, O.A., Zafar, A., Yasir, M., Alzarea, S.I., Alqinyah, M., and Khalid, M. (2022). Development of Ciprofloxacin-Loaded Bilosomes In-Situ Gel for Ocular Delivery: Optimization, In-Vitro Characterization, Ex-Vivo Permeation, and Antimicrobial Study. Gels, 8.10.3390/gels8110687 ↗
20. Development of acetazolamide loaded bilosomes for improved ocular delivery: Preparation, characterization and in vivo evaluation10.1016/j.jddst.2020.101910 ↗
21. Exploitation of the bilosome platform technology to formulate antibiotics and enhance efficacy of melioidosis treatments10.1016/j.jconrel.2019.02.002 ↗
22. Development and evaluation of luteolin loaded pegylated bilosome: Optimization, in vitro characterization, and cytotoxicity study10.1080/10717544.2021.2008055 ↗
23. Development of surface modified bilosomes for the oral delivery of quercetin: Optimization, characterization in-vitro antioxidant, antimicrobial, and cytotoxicity study10.1080/10717544.2022.2122634 ↗
24. Zafar, A., Alsaidan, O.A., Imam, S.S., Yasir, M., Alharbi, K.S., and Khalid, M. (2022). Formulation and Evaluation of Moxifloxacin Loaded Bilosomes In-Situ Gel: Optimization to Antibacterial Evaluation. Gels, 8.10.3390/gels8070418 ↗
25. Binsuwaidan, R., Sultan, A.A., Negm, W.A., Attallah, N.G.M., Alqahtani, M.J., Hussein, I.A., Shaldam, M.A., El-Sherbeni, S.A., and Elekhnawy, E. (2022). Bilosomes as nanoplatform for oral delivery and modulated in vivo antimicrobial activity of lycopene. Pharmaceuticals, 15.10.3390/ph15091043 ↗
26. Zafar, A., Imam, S.S., Alruwaili, N.K., Yasir, M., Alsaidan, O.A., Alshehri, S., Ghoneim, M.M., Khalid, M., Alquraini, A., and Alharthi, S.S. (2022). Formulation and Evaluation of Topical Nano-Lipid-Based Delivery of Butenafine: In Vitro Characterization and Antifungal Activity. Gels, 8.10.3390/gels8020133 ↗
27. Bilosomes nanocarriers for improved oral bioavailability of acyclovir: A complete characterization through in vitro, ex-vivo and in vivo assessment10.1016/j.jddst.2020.101634 ↗
28. Oral immunization against hepatitis B virus using mannosylated bilosomes
29. M-cell targeted delivery of recombinant hepatitis B surface antigen using cholera toxin B subunit conjugated bilosomes10.1016/j.ijpharm.2009.10.027 ↗
30. Characterization and optimization of bilosomes for oral vaccine delivery10.3109/1061186X.2012.747528 ↗
31. Premanand, B., Prabakaran, M., Kiener, T.K., and Kwang, J. (2013). Recombinant baculovirus associated with bilosomes as an oral vaccine candidate against HEV71 infection in mice. PLoS ONE, 8.10.1371/journal.pone.0055536 ↗
32. Rotavirus infection10.1038/nrdp.2017.83 ↗
33. Community acquired respiratory and gastrointestinal viral infections: Challenges in the immunocompromised host10.1097/QCO.0b013e328355660b ↗
34. Fungal Infections of the Gastrointestinal Tract10.1016/j.gtc.2021.02.009 ↗
35. Invasive candidiasis10.1038/nrdp.2018.26 ↗
36. Giardiasis: Characteristics, Pathogenesis and New Insights About Treatment10.2174/1568026618666181002095314 ↗
37. Parasitic infections of the gastrointestinal tract10.1016/S0889-8553(05)70211-9 ↗
38. Gastrointestinal Infections10.1128/microbiolspec.DMIH2-0005-2015 ↗
39. Impact of gastrointestinal parasitic nematodes of sheep, and the role of advanced molecular tools for exploring epidemiology and drug resistance—An Australian perspective10.1186/1756-3305-6-153 ↗
40. Intestinal amoebiasis: 160 years of its first detection and still remains as a health problem in developing countries10.1016/j.ijmm.2019.151358 ↗
41. The Potential of Milk-Derived Exosomes for Drug Delivery10.2174/1567201817666200817112503 ↗
42. Chemical Advances in Therapeutic Application of Exosomes and Liposomes10.2174/0929867329666220221094044 ↗
43. Anionic versus cationic bilosomes as oral nanocarriers for enhanced delivery of the hydrophilic drug risedronate10.1016/j.ijpharm.2019.04.069 ↗
44. Composition design and medical application of liposomes10.1016/j.ejmech.2019.01.007 ↗
45. Improvement of drug safety by the use of lipid-based nanocarriers10.1016/j.jconrel.2012.06.002 ↗
46. Lipid based nanocarriers: A translational perspective10.1016/j.nano.2018.05.021 ↗
47. Nanoencapsulation of carotenoids within lipid-based nanocarriers10.1016/j.jconrel.2019.02.005 ↗
48. Current approaches in lipid-based nanocarriers for oral drug delivery10.1007/s13346-021-00908-7 ↗
49. Liu, S., Tang, J., Ji, F., Lin, W., and Chen, S. (2022). Recent Advances in Zwitterionic Hydrogels: Preparation, Property, and Biomedical Application. Gels, 8.10.3390/gels8010046 ↗
50. Thiolated chitosans: A multi-talented class of polymers for various applications10.1021/acs.biomac.0c00663 ↗
51. Evaluating the effect of chitosan layer on bioaccessibility and cellular uptake of curcumin nanoemulsions10.1016/j.jfoodeng.2018.09.007 ↗
52. PEGylation for enhancing nanoparticle diffusion in mucus10.1016/j.addr.2017.08.010 ↗
53. Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse10.1016/j.jconrel.2014.10.026 ↗
54. Cellular uptake of self-emulsifying drug-delivery systems: Polyethylene glycol versus polyglycerol surface10.2217/nnm-2020-0127 ↗
55. Oral delivery of nanoparticles-let’s not forget about the protein corona10.1080/17425247.2019.1610384 ↗
56. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery10.1208/s12249-010-9563-0 ↗
57. Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes10.1016/j.ejps.2010.07.005 ↗
58. Influence of emulsifier structure on lipid bioaccessibility in oil–water nanoemulsions10.1021/jf401548r ↗
59. Shahzadi, I., Fürst, A., Knoll, P., and Bernkop-Schnürch, A. (2021). Nanostructured Lipid Carriers (NLCs) for Oral Peptide Drug Delivery: About the Impact of Surface Decoration. Pharmaceutics, 13.10.3390/pharmaceutics13081312 ↗
60. The emerging role of P-glycoprotein inhibitors in drug delivery: A patent review10.1517/13543776.2011.561784 ↗
61. Enhanced oral bioavailability of valsartan in rats using a supersaturable self-microemulsifying drug delivery system with P-glycoprotein inhibitors10.1080/10837450.2019.1683749 ↗
62. Effects of bile salts on the structural integrity of liposomes10.1016/0304-4165(78)90305-7 ↗
63. Preparation, characterization and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: Influences of fatty acids10.1016/j.colsurfb.2010.12.014 ↗
64. Oral self-nanoemulsifying formulation of GLP-1 agonist peptide exendin-4: Development, characterization and permeability assesment on Caco-2 cell monolayer10.1007/s00726-020-02926-0 ↗
65. Exendin-4 loaded nanoparticles with a lipid shell and aqueous core containing micelles for enhanced intestinal absorption10.1166/jbn.2015.1971 ↗
66. Self-nanoemulsifying drug delivery systems for oral insulin delivery: In vitro and in vivo evaluations of enteric coating and drug loading10.1016/j.ijpharm.2014.10.039 ↗
67. Novel solid lipid nanoparticle with endosomal escape function for oral delivery of insulin10.1021/acsami.8b00507 ↗
68. Bahman, F., Taurin, S., Altayeb, D., Taha, S., Bakhiet, M., and Greish, K. (2020). Oral insulin delivery using poly (styrene co-maleic acid) micelles in a diabetic mouse model. Pharmaceutics, 12.10.3390/pharmaceutics12111026 ↗
69. Development and evaluation of insulin-loaded cationic solid lipid nanoparticles for oral delivery10.1016/j.jddst.2016.10.012 ↗
70. Systematically designed chitosan-coated solid lipid nanoparticles of ferulic acid for effective management of Alzheimer’s disease: A preclinical evidence10.1016/j.colsurfb.2021.111838 ↗
71. Oral delivery of therapeutic peptides and proteins: Technology landscape of lipid-based nanocarriers10.1016/j.addr.2021.114097 ↗
72. Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutinin10.1016/j.vaccine.2003.11.067 ↗
73. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity10.1016/j.ymeth.2005.11.002 ↗
74. Oral immunization against hepatitis B using bile salt stabilized vesicles (bilosomes)10.18433/J3K01M ↗
75. Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano-bilosomes10.1111/j.1476-5381.2011.01452.x ↗
76. Review on Different Vesicular Drug Delivery Systems (VDDSs) and Their Applications10.2174/1872210516666220228150624 ↗
77. Oral mucosal immunization using glucomannosylated bilosomes10.1166/jbn.2014.1800 ↗
78. Improved stability and immunological potential of tetanus toxoid containing surface engineered bilosomes following oral administration10.1016/j.nano.2013.08.012 ↗
79. Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infection10.1016/j.vaccine.2009.03.040 ↗
80. A holistic review on Cryptococcus neoformans10.1016/j.micpath.2022.105521 ↗
81. Overview of selected virulence attributes in Aspergillus fumigatus, Candida albicans, Cryptococcus neoformans, Trichophyton rubrum, and Exophiala dermatitidis10.1016/j.fgb.2017.10.008 ↗
82. Studying fungal pathogens of humans and fungal infections: Fungal diversity and diversity of approaches10.1016/j.micinf.2019.06.011 ↗
83. Antimicrobial phyto-photodynamic activity inducing by polyphenol-supported Methylene Blue co-loaded into multifunctional bilosomes: Advanced hybrid nanoplatform in the skin infections treatment?10.1016/j.jphotobiol.2023.112650 ↗
84. Gastrointestinal infections10.5152/ced.2013.1509 ↗
85. Bilosomes as effective delivery systems to improve the gastrointestinal stability and bioavailability of epigallocatechin gallate (EGCG)10.1016/j.foodres.2021.110631 ↗
86. Investigating superiority of novel bilosomes over niosomes in the transdermal delivery of diacerein: In vitro characterization, ex vivo permeation and in vivo skin deposition study10.1080/08982104.2018.1430831 ↗